Medicines planning
51 results
Applied filters
Preparing to use denosumab 120mg biosimilar
14 November 2025Biosimilars of denosumab 120mg (Xgeva) are expected soon. We offer general information and implementation advice.
Preparing to use ranibizumab biosimilar
5 November 2025Ranibizumab biosimilar needs planning. Ensure you are familiar with the area and then develop an implementation plan working with the multidisciplinary team
The licence and supporting evidence for ranibizumab biosimilars
5 November 2025Four licensed ranibizumab biosimilars are available: Byooviz, Ongavia, Rimmyrah and Ximluci. Learn about the licensed indications and supporting evidence
Annual medicines planning publication, Prescribing Outlook
30 October 2025Our annual output to support managed entry and budget planning for new medicines, new indications and patent expiries in the NHS.
Preparing to use golimumab biosimilar
17 October 2025Golimumab biosimilars are expected soon. We offer general information and implementation advice.
Primary care discussions: biosimilar insulin
30 September 2025Discussion about the considerations of implementing biosimilar insulin in primary care. Hints and tips for systems considering a move to biosimilar insulin.
Preparing to use omalizumab biosimilar
19 September 2025Omalizumab biosimilars are expected soon. We offer general information and implementation advice.
Understanding biosimilar and generic market entry
12 September 2025New medicines have several protections against competition. Other factors influence availability of biosimilars or generics after loss of exclusivity.
Biosimilar and key generic medicines – September 2025 update
11 September 2025An update about biosimilar and key generic medicines to support system mobilisation.
The licence and supporting evidence for tocilizumab biosimilar
1 September 2025One licensed tocilizumab biosimilar is available: Tyenne. Learn about the licensed indications, supporting evidence and key differences.